Summary
Enrollment to the ProAgio study was completed this year and data are currently under analysis, including scientific correlatives being performed on patient samples. We have identified a safe dose of ProAgio to give to patients and found that several patients receiving the preferred dose experienced prolonged stable disease with little to no drug toxicity. Pre-clinical studies examining ProAgio effect on the pancreatic tumor microenvironment in co-clinical study in KPC mice have been completed and a manuscript describing the findings is in preparation.
